Cargando…

Cytomegalovirus mismatch after heart transplantation: Impact of antiviral prophylaxis and intravenous hyperimmune globulin

OBJECTIVE: Cytomegalovirus (CMV) infections are correlated with complications following heart transplantation (HTx) and impaired outcome. The impact of a serologic mismatch between donor and recipient and the necessity of prophylactic virostatic medication is still a matter of concern. METHODS: We r...

Descripción completa

Detalles Bibliográficos
Autores principales: Immohr, Moritz B., Akhyari, Payam, Böttger, Charlotte, Mehdiani, Arash, Dalyanoglu, Hannan, Westenfeld, Ralf, Oehler, Daniel, Tudorache, Igor, Aubin, Hug, Lichtenberg, Artur, Boeken, Udo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589400/
https://www.ncbi.nlm.nih.gov/pubmed/34525263
http://dx.doi.org/10.1002/iid3.508
_version_ 1784598705694834688
author Immohr, Moritz B.
Akhyari, Payam
Böttger, Charlotte
Mehdiani, Arash
Dalyanoglu, Hannan
Westenfeld, Ralf
Oehler, Daniel
Tudorache, Igor
Aubin, Hug
Lichtenberg, Artur
Boeken, Udo
author_facet Immohr, Moritz B.
Akhyari, Payam
Böttger, Charlotte
Mehdiani, Arash
Dalyanoglu, Hannan
Westenfeld, Ralf
Oehler, Daniel
Tudorache, Igor
Aubin, Hug
Lichtenberg, Artur
Boeken, Udo
author_sort Immohr, Moritz B.
collection PubMed
description OBJECTIVE: Cytomegalovirus (CMV) infections are correlated with complications following heart transplantation (HTx) and impaired outcome. The impact of a serologic mismatch between donor and recipient and the necessity of prophylactic virostatic medication is still a matter of concern. METHODS: We retrospectively reviewed all patients that underwent HTx between 2010 and 2020 in our department. The recipients (n = 176) could be categorized into four risk groups depending on their serologic CMV matching (D(+)/R( − ) = donor CMV‐IgG positive and recipient CMV‐IgG negative, n = 32; D( − )/R(+), n = 51; D( − )/R( − ), n = 35; D(+)/R(+), n = 58). All patients followed the same protocol of CMV prophylaxis with application of ganciclovir/valganciclovir and intravenous CMV hyperimmune globulin. RESULTS: Incidence of postoperative morbidity such as primary graft dysfunction, neurological events, infections, and graft rejection were comparable between all groups (p > .05). However, the incidence of postoperative acute kidney injury with hemodialysis was by trend increased in the D(−)/R(+) group (72.0%) compared to the other groups. In‐hospital CMV‐DNAemia was observed in serologic positive recipients only (D(+)/R(−): 0.0%, D(−)/R(+): 25.0%, D(−)/R(−): 0.0%, D(+)/R(+): 13.3%, p < .01). During the first year, a total of 18 patients developed CMV‐DNAemia (D(+)/R(−): 31.6%, D(−)/R(+): 31.9%, D(−)/R(−): 3.4%, D(+)/R(+): 11.1%, p = .03). CONCLUSIONS: Seropositive recipients carry an important risk for CMV‐DNAemia. However, we did not observe differences in perioperative morbidity and mortality regarding CMV matching, which might be related to regularly administer prophylactic virostatics and additional CMV‐IVIG for risk constellations. For high‐risk constellation, long‐term application of CMV‐IVIG during the first year after transplant may be beneficial.
format Online
Article
Text
id pubmed-8589400
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-85894002021-11-19 Cytomegalovirus mismatch after heart transplantation: Impact of antiviral prophylaxis and intravenous hyperimmune globulin Immohr, Moritz B. Akhyari, Payam Böttger, Charlotte Mehdiani, Arash Dalyanoglu, Hannan Westenfeld, Ralf Oehler, Daniel Tudorache, Igor Aubin, Hug Lichtenberg, Artur Boeken, Udo Immun Inflamm Dis Original Articles OBJECTIVE: Cytomegalovirus (CMV) infections are correlated with complications following heart transplantation (HTx) and impaired outcome. The impact of a serologic mismatch between donor and recipient and the necessity of prophylactic virostatic medication is still a matter of concern. METHODS: We retrospectively reviewed all patients that underwent HTx between 2010 and 2020 in our department. The recipients (n = 176) could be categorized into four risk groups depending on their serologic CMV matching (D(+)/R( − ) = donor CMV‐IgG positive and recipient CMV‐IgG negative, n = 32; D( − )/R(+), n = 51; D( − )/R( − ), n = 35; D(+)/R(+), n = 58). All patients followed the same protocol of CMV prophylaxis with application of ganciclovir/valganciclovir and intravenous CMV hyperimmune globulin. RESULTS: Incidence of postoperative morbidity such as primary graft dysfunction, neurological events, infections, and graft rejection were comparable between all groups (p > .05). However, the incidence of postoperative acute kidney injury with hemodialysis was by trend increased in the D(−)/R(+) group (72.0%) compared to the other groups. In‐hospital CMV‐DNAemia was observed in serologic positive recipients only (D(+)/R(−): 0.0%, D(−)/R(+): 25.0%, D(−)/R(−): 0.0%, D(+)/R(+): 13.3%, p < .01). During the first year, a total of 18 patients developed CMV‐DNAemia (D(+)/R(−): 31.6%, D(−)/R(+): 31.9%, D(−)/R(−): 3.4%, D(+)/R(+): 11.1%, p = .03). CONCLUSIONS: Seropositive recipients carry an important risk for CMV‐DNAemia. However, we did not observe differences in perioperative morbidity and mortality regarding CMV matching, which might be related to regularly administer prophylactic virostatics and additional CMV‐IVIG for risk constellations. For high‐risk constellation, long‐term application of CMV‐IVIG during the first year after transplant may be beneficial. John Wiley and Sons Inc. 2021-09-15 /pmc/articles/PMC8589400/ /pubmed/34525263 http://dx.doi.org/10.1002/iid3.508 Text en © 2021 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Immohr, Moritz B.
Akhyari, Payam
Böttger, Charlotte
Mehdiani, Arash
Dalyanoglu, Hannan
Westenfeld, Ralf
Oehler, Daniel
Tudorache, Igor
Aubin, Hug
Lichtenberg, Artur
Boeken, Udo
Cytomegalovirus mismatch after heart transplantation: Impact of antiviral prophylaxis and intravenous hyperimmune globulin
title Cytomegalovirus mismatch after heart transplantation: Impact of antiviral prophylaxis and intravenous hyperimmune globulin
title_full Cytomegalovirus mismatch after heart transplantation: Impact of antiviral prophylaxis and intravenous hyperimmune globulin
title_fullStr Cytomegalovirus mismatch after heart transplantation: Impact of antiviral prophylaxis and intravenous hyperimmune globulin
title_full_unstemmed Cytomegalovirus mismatch after heart transplantation: Impact of antiviral prophylaxis and intravenous hyperimmune globulin
title_short Cytomegalovirus mismatch after heart transplantation: Impact of antiviral prophylaxis and intravenous hyperimmune globulin
title_sort cytomegalovirus mismatch after heart transplantation: impact of antiviral prophylaxis and intravenous hyperimmune globulin
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589400/
https://www.ncbi.nlm.nih.gov/pubmed/34525263
http://dx.doi.org/10.1002/iid3.508
work_keys_str_mv AT immohrmoritzb cytomegalovirusmismatchafterhearttransplantationimpactofantiviralprophylaxisandintravenoushyperimmuneglobulin
AT akhyaripayam cytomegalovirusmismatchafterhearttransplantationimpactofantiviralprophylaxisandintravenoushyperimmuneglobulin
AT bottgercharlotte cytomegalovirusmismatchafterhearttransplantationimpactofantiviralprophylaxisandintravenoushyperimmuneglobulin
AT mehdianiarash cytomegalovirusmismatchafterhearttransplantationimpactofantiviralprophylaxisandintravenoushyperimmuneglobulin
AT dalyanogluhannan cytomegalovirusmismatchafterhearttransplantationimpactofantiviralprophylaxisandintravenoushyperimmuneglobulin
AT westenfeldralf cytomegalovirusmismatchafterhearttransplantationimpactofantiviralprophylaxisandintravenoushyperimmuneglobulin
AT oehlerdaniel cytomegalovirusmismatchafterhearttransplantationimpactofantiviralprophylaxisandintravenoushyperimmuneglobulin
AT tudoracheigor cytomegalovirusmismatchafterhearttransplantationimpactofantiviralprophylaxisandintravenoushyperimmuneglobulin
AT aubinhug cytomegalovirusmismatchafterhearttransplantationimpactofantiviralprophylaxisandintravenoushyperimmuneglobulin
AT lichtenbergartur cytomegalovirusmismatchafterhearttransplantationimpactofantiviralprophylaxisandintravenoushyperimmuneglobulin
AT boekenudo cytomegalovirusmismatchafterhearttransplantationimpactofantiviralprophylaxisandintravenoushyperimmuneglobulin